Dasatinib Drugs Market is Estimated to Witness High Growth Owing to Increasing Prevalence of Leukemia


 Dasatinib, sold under the brand name Sprycel among others, is a chemotherapy medication used to treat chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). Dasatinib is a second-generation tyrosine kinase inhibitor which is a safer and more effective alternative to imatinib for the treatment of CML. It works by blocking proteins called tyrosine kinases that help cancer cells grow. The global dasatinib drugs market offers advantages such as high tolerance, fewer side effects, and convenient oral dosing over other chemotherapy drugs. The need for effective drugs to treat blood cancer such as leukemia is increasing with rising prevalence of the disease globally.


The global dasatinib drugs market is estimated to be valued at US$ 1350.06 Mn in 2023 and is expected to exhibit a CAGR of 6.8% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Opportunity:
Increasing Prevalence of Leukemia
The market opportunity lies in the rising prevalence of leukemia globally which is increasing the demand for dasatinib drugs for its effective treatment. Leukemia is the most common type of childhood cancer and its incidence is also increasing among adults. As per statistics, there were around 67,000 new cases of leukemia reported in the United States in 2021. The growing geriatric population also contributes to the increasing burden of leukemia as the risk is higher among older adults. Effective treatment options like dasatinib drugs will witness high demand with growing leukemia patient pool, presenting lucrative opportunities for players in the dasatinib drugs market.

Porter’s Analysis
Threat of new entrants: The threat of new entrants is moderate as the dasatinib drugs market requires substantial R&D investments and clinical trial timelines to develop new drugs. However, generics offer lower barriers.
Bargaining power of buyers: The bargaining power of buyers is moderate to high given the availability of substitutes and generic alternatives. Buyers can negotiate on price points.
Bargaining power of suppliers: The bargaining power of suppliers is moderate given that key raw material suppliers have a widespread global presence. However, supply chain disruptions can impact prices.
Threat of new substitutes: The threat of new substitutes is high as newer targeted therapies continuously emerge for cancer treatment. Hence innovation is critical to sustain in this space.
Competitive rivalry: The competitive rivalry is high among existing players given the focus on patent protections, portfolio expansion, and market share gains.

SWOT Analysis
Strengths: Established drug portfolios, global presence, robust pipeline and clinical trials, strategic collaborations and partnerships.
Weaknesses: High R&D costs, regulatory approvals and pricing pressures, patent expirations of blockbuster drugs.
Opportunities: Emerging markets growth, expanding indications, combinations and sequential therapies, personalized medicine trends.
Threats: Generic competition post patent expiry, slower uptake of high priced brands, strict regulations.

Key Takeaways
The global Dasatinib Drugs market is expected to witness high growth over the forecast period of 2023 to 2030 supported by rising cancer incidence, increasing approvals for newer lines of therapy and geographical expansions into high potential regions.

Regional analysis: Asia Pacific is poised to witness fastest growth during the forecast period led by the large patient pools in countries like India and China, availability of affordable generics and improving access and affordability of cancer care. The market is also projected to generate lucrative opportunities in other emerging regions like Latin America and Middle East & Africa over the coming years.

Key players: Key players operating in the dasatinib drugs market are Bristol-Myers Squibb Company, MSN Labs, Lupin, Dr. Reddy’s Laboratories, Gilead Sciences, Inc., Hetero Labs, MANUS AKTTEVA BIOPHARMA LLP, Alembic Pharma, JINLAN Pharm-Drugs Technology Co., Ltd., and Zhejiang Hisun Pharma. Bristol-Myers Squibb holds a dominant share while generic manufacturers are engaging in partnerships and capacity expansions to gain market share.

Comments

Post a Comment

Popular posts from this blog

Unveiling Health Secrets: Exploring the Potential of Blood-Based Biomarkers

Image
  The human body is a complex and intricate system, often harboring subtle signs of its inner workings. One of the most promising avenues for unlocking these secrets lies within our bloodstream – a treasure trove of information encoded in the form of blood-based biomarkers. These biomarkers, measurable indicators present in the blood, hold the potential to revolutionize healthcare by providing early detection, accurate diagnosis, and personalized treatment approaches. Blood-based biomarkers encompass a wide range of molecules – from proteins and nucleic acids to metabolites and even circulating cells. Researchers have been diligently working to identify specific biomarkers associated with various diseases and conditions. For instance, elevated levels of certain proteins might point to cardiovascular diseases, while specific genetic material could indicate the presence of cancer. By analyzing these biomarkers, clinicians gain valuable insights into an individual's health status, en...
Read more

Revolutionizing Biology: Advancements in Single Cell Analysis Techniques

Image
  Single cell analysis has emerged as a groundbreaking technology that is revolutionizing the field of biology. Traditionally, biological studies were conducted on populations of cells, averaging out the heterogeneity present within them. However, the advent of single cell analysis has enabled scientists to delve into the complexity of individual cells, uncovering a wealth of previously inaccessible information. Advancements in single cell analysis techniques have paved the way for a deeper understanding of cellular heterogeneity, gene expression, and cellular behavior. One of the most remarkable techniques is single-cell RNA sequencing (scRNA-seq), which allows scientists to measure gene expression in individual cells. This breakthrough has led to the identification of rare cell types, understanding of cellular communication networks, and the discovery of novel biomarkers. Moreover, single cell imaging techniques, such as single cell fluorescence microscopy, have enabled research...
Read more

Medical Robots Market Poised to Grow Owing to Improving Healthcare Infrastructure

Image
 The Medical Robots Market is anticipated to witness robust growth due to rising healthcare spending across the globe. Medical robots are used to perform minimal invasive surgeries with greater accuracy and flexibility. Growing preference for Robot-Assisted Surgery (RAS) over conventional open surgeries due to benefits such as shorter recovery time and minimum operative scars has been augmenting demand for medical robots. Key functions include guiding and positioning surgical accessories like guide tubes in radiology and guiding catheter and wires in cardiology. With rising chronic disease prevalence associated with aging populations, the need for more surgical procedures is surging which requires precise action minimally invasive robotic systems can provide. The Global Medical Robots Market is estimated to be valued at US$ 11.47 Bn in 2024 and is expected to exhibit a CAGR of 16% over the forecast period 2023 to 2030. Key Takeaways: Key players operating in the Medical Robo...
Read more